Small/Middle Tier Cities and County Lung Cancer Quality Improvement Project (QIP) Study
← catalyst calendarNCT06494241 · readout in 466 d
Sponsored by AstraZeneca (industry) · AZN — their whole pipeline →.
Phase
—
Status
Active, not recruiting
Study type
Observational
Enrollment
1,000actual
Sites
46
Country
China
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2024-11-22 | actual | When the study began enrolling |
| Primary completion | 2027-11-28 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2027-11-28 | estimated | The whole study's end, after follow-up |
| First posted | 2024-07-10 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-06-02 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Carcinoma, Non-Small-Cell Lung
- Lung Neoplasms
- Respiratory Tract Neoplasms
- Thoracic Neoplasms
- Neoplasms by Site
- Neoplasms
- Lung Diseases
- Respiratory Tract Diseases
- Carcinoma, Bronchogenic
- Bronchial Neoplasms
Primary outcomes
what the primary-completion date above is the date OFTo evaluate the molecular testing pattern in metastatic NSCLC patients after QIP
measured Approximately 1 month after last patient in
To evaluate the treatment pattern in metastatic NSCLC patients after QIP
measured Approximately 1 month after last patient in
Permalink · AZN's whole pipeline · Catalyst calendar · Every registered study · What changed